Beacon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 06-12-2024
- Paid Up Capital ₹ 3.07 M
as on 06-12-2024
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.87 M
as on 06-12-2024
- Revenue %
(FY 2020)
- Profit 30.98%
(FY 2020)
- Ebitda 17.35%
(FY 2020)
- Net Worth -17.28%
(FY 2020)
- Total Assets 205.87%
(FY 2020)
About Beacon Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.07 M.
The company currently has active open charges totaling ₹5.87 M.
Shankar Singh and Sekhar Datta serve as directors at the Company.
- CIN/LLPIN
U24232WB1995PTC072233
- Company No.
072233
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jun 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Beacon Pharmaceuticals Pvt Ltd offer?
Beacon Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Mineral Supplement, Carbonyl Iron Capsules, Antibiotic Tablets & Capsules, Azithromycin Tablets, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Calcium Tablet, Calcium Carbonate Tablet.
Who are the key members and board of directors at Beacon Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shankar Singh  | Additional Director | 11-Dec-2018 | Current |
| Sekhar Datta | Director | 06-May-2016 | Current |
Financial Performance of Beacon Pharmaceuticals.
Beacon Pharmaceuticals Pvt Ltd, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 30.98% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Beacon Pharmaceuticals?
In 2016, Beacon Pharmaceuticals had a promoter holding of 50.21% and a public holding of 49.79%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Allahabad Bank Creation Date: 24 Mar 2012 | ₹0.29 M | Open |
Allahabad Bank Creation Date: 13 Jun 2000 | ₹5.58 M | Open |
How Many Employees Work at Beacon Pharmaceuticals?
Unlock and access historical data on people associated with Beacon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Beacon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Beacon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
